Phil B.FontanarosaMD, Deputy EditorIndividualAuthorMargaret A.WinkerMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor
Copyright 2000 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2000
To the Editor: The incidence of cutaneous malignant
melanoma is increasing more rapidly than that of any other cancer among the
white population.1 Melanomas cause more
than 75% of all skin cancer deaths.2 Because
the Breslow3 thickness of a primary tumor
is related to its metastatic potential, this factor often guides surgical
management. However, some thin melanomas can metastasize despite a favorable
Breslow thickness.4 Therefore, better prognostic factors are required
for definition of malignant potential.
Strebhardt, K, Kneisel L, Linhart C, Bernd A, Kaufmann R. Prognostic Value of Pololike Kinase Expression in Melanomas. JAMA. 2000;283(4):479-480. doi:10.1001/jama.283.4.475